1.Contrast-enhanced ultrasound and contrast-enhanced computed tomography for differentiating mass-forming pancreatitis from pancreatic ductal adenocarcinoma: a meta-analysis.
Jie YANG ; Jiayan HUANG ; Yonggang ZHANG ; Keyu ZENG ; Min LIAO ; Zhenpeng JIANG ; Wuyongga BAO ; Qiang LU
Chinese Medical Journal 2023;136(17):2028-2036
BACKGROUND:
Patients with mass-forming pancreatitis (MFP) or pancreatic ductal adenocarcinoma (PDAC) presented similar clinical symptoms, but required different treatment approaches and had different survival outcomes. This meta-analysis aimed to compare the diagnostic performance of contrast-enhanced ultrasound (CEUS) and contrast-enhanced computed tomography (CECT) in differentiating MFP from PDAC.
METHODS:
A literature search was performed in the PubMed, EMBASE (Ovid), Cochrane Library (CENTRAL), China National Knowledge Infrastructure (CNKI), Weipu (VIP), and WanFang databases to identify original studies published from inception to August 20, 2021. Studies reporting the diagnostic performances of CEUS and CECT for differentiating MFP from PDAC were included. The meta-analysis was performed with Stata 15.0 software. The outcomes included the pooled sensitivity, specificity, positive likelihood ratio (+LR), negative likelihood ratio (-LR), diagnostic odds ratio (DOR), and summary receiver operating characteristic (SROC) curves of CEUS and CECT. Meta-regression was conducted to investigate heterogeneity. Bayesian network meta-analysis was conducted to indirectly compare the overall diagnostic performance.
RESULTS:
Twenty-six studies with 2115 pancreatic masses were included. The pooled sensitivity and specificity of CEUS for MFP were 82% (95% confidence interval [CI], 73%-88%; I2 = 0.00%) and 95% (95% CI, 90%-97%; I2 = 63.44%), respectively; the overall +LR, -LR, and DOR values were 15.12 (95% CI, 7.61-30.01), 0.19 (95% CI, 0.13-0.29), and 78.91 (95% CI, 30.94-201.27), respectively; and the area under the SROC curve (AUC) was 0.90 (95% CI, 0.87-92). However, the overall sensitivity and specificity of CECT were 81% (95% CI, 75-85%; I2 = 66.37%) and 94% (95% CI, 90-96%; I2 = 74.87%); the overall +LR, -LR, and DOR values were 12.91 (95% CI, 7.86-21.20), 0.21 (95% CI, 0.16-0.27), and 62.53 (95% CI, 34.45-113.51), respectively; and, the SROC AUC was 0.92 (95% CI, 0.90-0.94). The overall diagnostic accuracy of CEUS was comparable to that of CECT for the differential diagnosis of MFP and PDAC (relative DOR 1.26, 95% CI [0.42-3.83], P > 0.05).
CONCLUSIONS
CEUS and CECT have comparable diagnostic performance for differentiating MFP from PDAC, and should be considered as mutually complementary diagnostic tools for suspected focal pancreatic lesions.
Humans
;
Contrast Media
;
Bayes Theorem
;
Tomography, X-Ray Computed/methods*
;
Pancreatic Neoplasms/diagnostic imaging*
;
Carcinoma, Pancreatic Ductal/diagnostic imaging*
;
Sensitivity and Specificity
;
Pancreatitis/diagnostic imaging*
;
Ultrasonography/methods*
2.Current Status of Endoscopic Ultrasound Techniques for Pancreatic Neoplasms
Yousuke NAKAI ; Naminatsu TAKAHARA ; Suguru MIZUNO ; Hirofumi KOGURE ; Kazuhiko KOIKE
Clinical Endoscopy 2019;52(6):527-532
Endoscopic ultrasound (EUS) now plays an important role in the management of pancreatic neoplasms. There are various types of pancreatic neoplasms, from benign to malignant lesions, and the role of EUS ranges from the imaging diagnosis to treatment. EUS is useful for the detection, characterization, and tissue acquisition of pancreatic lesions. Recent advancement of contrast-enhanced harmonic EUS and elastography enables better characterization of pancreatic lesions. In addition to these enhanced EUS imaging techniques, EUS-guided tissue acquisition is now the standard procedure to establish the pathological diagnosis of pancreatic neoplasms. While these diagnostic roles of EUS have been established, EUS-guided interventions such as ablation and drainage are also increasingly utilized in the management of pancreatic neoplasms. However, most of these EUS-guided interventions are not yet standardized in terms of techniques and devices and thus need further investigations.
Biopsy, Fine-Needle
;
Diagnosis
;
Drainage
;
Elasticity Imaging Techniques
;
Endosonography
;
Pancreatic Neoplasms
;
Ultrasonography
3.Pancreatic Cystic Neoplasm: Radiologic Evaluation and Differential Diagnosis
Korean Journal of Pancreas and Biliary Tract 2019;24(4):141-146
Pancreatic cystic neoplasm is a clinically challenging entity. Its incidence estimated up to 45% of the general population. The biological behavior ranges from benign to malignant disease. The strategy for pancreatic cystic neoplasm could be to prevent progression to pancreatic cancer while minimizing the costs. The first step for the correct management is correct diagnosis. In this paper, the radiological differential diagnosis of them will be described.
Diagnosis
;
Diagnosis, Differential
;
Incidence
;
Pancreatic Cyst
;
Pancreatic Neoplasms
;
Ultrasonography
4.Extraordinary Response of Metastatic Pancreatic Cancer to Chemotherapy
Dong Woo SHIN ; Jinkook KIM ; Jong Chan LEE ; Jaihwan KIM ; Jin Hyeok HWANG
Journal of Digestive Cancer Report 2019;7(1):22-25
A 58-year-old woman presented with right flank and back pain for one month. After undergoing an abdominal computed tomography (CT), she was referred to our hospital. The abdominal CT showed a hypodense pancreatic tail mass with multiple retroperitoneal lymph node metastases. Positron emission tomography-computed tomography (PET-CT) scan showed high 18F-FDG uptake in pancreatic tumor and enlarged lymph nodes. Endoscopic ultrasound fine needle aspiration (EUS-FNA) revealed adenocarcinoma, which stained strongly in hENT1 (human equilibrative nucleoside transporter 1) on immunohistochemistry. She received gemcitabine 1,000 mg/m² + nanoparticle albumin-bound paclitaxel 125 mg/m² as a palliative chemotherapy. Follow-up abdominal CT and PET-CT after 4 cycles of chemotherapy showed that both pancreatic mass and the metastatic retroperitoneal lymph nodes were nearly disappeared. We report a case of 58-year-old female with metastatic pancreatic cancer who had a dramatic response to palliative chemotherapy (gemcitabine plus nanoparticle albumin-bound paclitaxel).
Adenocarcinoma
;
Albumin-Bound Paclitaxel
;
Back Pain
;
Biopsy, Fine-Needle
;
Drug Therapy
;
Electrons
;
Female
;
Fluorodeoxyglucose F18
;
Follow-Up Studies
;
Humans
;
Immunohistochemistry
;
Lymph Nodes
;
Middle Aged
;
Nanoparticles
;
Neoplasm Metastasis
;
Nucleoside Transport Proteins
;
Pancreatic Neoplasms
;
Tail
;
Tomography, X-Ray Computed
;
Ultrasonography
5.Clinical usefulness of fluorodeoxyglucose-positron emission tomography/computed tomography and carbohydrate antigen 19-9 in patients with periampullary tumors
Jeong Eon KIM ; Min Ho SHIN ; Nam Kyu CHOI
Korean Journal of Clinical Oncology 2019;15(2):56-60
PURPOSE: The prognosis of periampullary cancer varies with its origin and early diagnosis influences outcome. Endoscopic ultrasound, computed tomography, fine needle aspiration, and fluorodeoxyglucose-positron emission tomography/computed tomography (¹⁸FDG-PET/CT) are helpful for diagnosis. This study evaluates the diagnostic efficacy of ¹⁸FDG-PET for preoperative periampullary tumors.METHODS: A series of 100 patients undergoing ¹⁸FDG-PET/CT before surgical resection of periampullary tumors between March 2011 and February 2019 were enrolled. Maximum standardized uptake value (SUVmax) and carbohydrate antigen 19-9 (CA19-9) levels were compared with pathohistological confirmation of periampullary tumors.RESULTS: The SUVmax and uptake range varied with the origin of the periampullary tumors. The SUVmax was not available for 17 of the 42 pancreas tumors, three of 30 common bile duct tumors, and four of 18 ampulla of Vater tumors. The median SUVmax was 0.0 in benign tumors and 5.05 in malignant tumors. The mean SUVmax was 4.1±5.6 in pancreatic tumors, 3.9±2.4 in ampulla of Vater, and 6.0±3.7 in common bile duct. The SUVmax was higher in common bile duct tumors than others. CA19-9 level was of diagnostic value in pancreatic tumor patients. The median CA19-9 levels were 7.64 U/mL (range, 2.71–45.05 U/mL) in benign tumors and 91.97 U/mL (range, 26.91–276.60 U/mL) in cancers patients.CONCLUSION: Preoperative SUVmax and CA19-9 level were of diagnostic value for periampullary tumors originating in the pancreas.
Ampulla of Vater
;
Biopsy, Fine-Needle
;
CA-19-9 Antigen
;
Common Bile Duct
;
Diagnosis
;
Early Diagnosis
;
Fluorodeoxyglucose F18
;
Humans
;
Pancreas
;
Pancreatic Neoplasms
;
Prognosis
;
Ultrasonography
6.Endoscopic Ultrasound in the Diagnosis of Pancreatoduodenal Groove Pathology: Report of Three Cases and Brief Review of the Literature
Inés C ORÍA ; Juan E PIZZALA ; Augusto M VILLAVERDE ; Juan C SPINA ; Analía V PASQUA ; Julio C LAZARTE ; Oscar M MAZZA ; Mariano M MARCOLONGO
Clinical Endoscopy 2019;52(2):196-200
The pancreatoduodenal groove is a small area where pathologic processes involving the distal bile duct, duodenum, pancreatic head, ampulla of Vater, and retroperitoneum converge. Despite great advances in imaging techniques, a definitive preoperative diagnosis is challenging because of the complex anatomy of this area. Therefore, surgical intervention is frequently required because of the inability to completely exclude malignancy. We report 3 cases of patients with different groove pathologies but similar clinical and imaging presentation, and show the essential role of endoscopic ultrasound (EUS) in making a specific preoperative diagnosis, excluding malignancy in the first case, changing diagnosis in the second case, and confirming malignancy in the third case. EUS was a fundamental tool in this cohort of patients, not only because of its ability to provide superior visualization of a difficult anatomical region, but because of the ability to guide precise, real-time procedures, such as fine-needle aspiration.
Ampulla of Vater
;
Bile Ducts
;
Biopsy, Fine-Needle
;
Cohort Studies
;
Diagnosis
;
Duodenum
;
Head
;
Humans
;
Pancreatic Neoplasms
;
Pathologic Processes
;
Pathology
;
Ultrasonography
7.Endoscopic Palliation for Biliary and Pancreatic Malignancies: Recent Advances
Zaheer NABI ; D Nageshwar REDDY
Clinical Endoscopy 2019;52(3):226-234
Malignancies of the pancreatobiliary system are usually unresectable at the time of diagnosis. As a consequence, a majority of these cases are candidates for palliative care. With advances in chemotherapeutic agents and multidisciplinary care, the survival rate in pancreatobiliary malignancies has improved. Therefore, there is a need to provide an effective and long-lasting palliative care for these patients. Endoscopic palliation is preferred to surgery as the former is associated with equal efficacy and reduced morbidity. The main role of endoscopic palliation in the vast majority of pancreatobiliary malignancies includes biliary and enteral stenting for malignant obstructive jaundice and gastric outlet obstruction, respectively. Recent advances in endoscopic palliation appear promising in imparting long-lasting relief of symptoms. Use of radiofrequency ablation and photodynamic therapy in malignant biliary obstruction has been shown to improve the survival rates as well as the patency of biliary stents. The emergence of endoscopic ultrasound (EUS) as a therapeutic tool has enhanced the capability of minimally invasive palliation in pancreatobiliary cancers. EUS is a valuable alternative to endoscopic retrograde cholangiopancreatography for the palliation of obstructive jaundice. More recently, EUS is emerging as an effective primary modality for biliary and gastric bypass.
Catheter Ablation
;
Cholangiopancreatography, Endoscopic Retrograde
;
Diagnosis
;
Gastric Bypass
;
Gastric Outlet Obstruction
;
Humans
;
Jaundice, Obstructive
;
Palliative Care
;
Pancreatic Neoplasms
;
Photochemotherapy
;
Stents
;
Survival Rate
;
Ultrasonography
8.Endoscopic Ultrasound-Guided Transgastric Drainage of an Intra-Abdominal Abscess following Gastrectomy
Satoru KIKUCHI ; Tetsushi KUBOTA ; Shinji KURODA ; Masahiko NISHIZAKI ; Shunsuke KAGAWA ; Hironari KATO ; Hiroyuki OKADA ; Toshiyoshi FUJIWARA
Clinical Endoscopy 2019;52(4):373-376
Endoscopic ultrasound (EUS)-guided transgastric drainage has been performed as a less invasive procedure for pancreatic fistulas and intra-abdominal abscesses occurring after surgery in recent years. However, there are no reports of EUS-guided transgastric drainage of intra-abdominal abscesses following gastrectomy. This case report describes 2 patients who developed an intra-abdominal abscess following gastrectomy and underwent EUS-guided transgastric drainage. Both patients underwent laparoscopy-assisted distal gastrectomy with Billroth-I reconstruction for gastric cancer. The intra-abdominal abscesses were caused by postoperative pancreatic fistula that developed following gastrectomy. One patient underwent naso-cystic drainage and the other underwent only a needle puncture of the abscess cavity. EUS-guided drainage was performed safely and effectively, although 1 patient developed gastroduodenal anastomotic leakage related to this procedure. In summary, EUS-guided transgastric drainage is safe and technically feasible even in post-gastrectomy patients. However, it is necessary to be careful if this procedure is performed in the early period following gastrectomy.
Abdominal Abscess
;
Abscess
;
Anastomotic Leak
;
Drainage
;
Gastrectomy
;
Humans
;
Needles
;
Pancreatic Fistula
;
Punctures
;
Stomach Neoplasms
;
Ultrasonography
9.The Role of Endoscopic Ultrasound in Early Detection of Pancreatic Cancer
Sung Woo KO ; Jun Seong HWANG ; Tae Jun SONG
Korean Journal of Pancreas and Biliary Tract 2019;24(3):102-110
Pancreatic cancer was the 9th most common cancer in Korea in 2016, and the incidence is on the rise. Despite advances in diagnostic and therapeutic methods, 5-year survival rate of pancreatic cancer is about 11.7% in Korea, and its prognosis is very poor compared to other cancers. At present, although complete surgical resection is the most effective treatment, only less than 20% of patients are even candidates for resection because diagnosis is usually delayed. So early detection of pancreatic cancer is one of the main objective in the treatment of pancreatic cancer. Among imaging modalities, computed tomography-scan is the most widely available, and the most frequently used. However as endoscopic ultrasound (EUS) techniques have evolved and based on the results of researches that EUS is superior to computed tomography-scan in the diagnosis of small pancreatic tumor, the role of EUS in the early diagnosis of pancreatic cancer is attracting attention. Herein, the authors focused on the role of EUS in early pancreatic cancer.
Diagnosis
;
Early Diagnosis
;
Endoscopic Ultrasound-Guided Fine Needle Aspiration
;
Endosonography
;
Humans
;
Incidence
;
Korea
;
Pancreatic Neoplasms
;
Prognosis
;
Survival Rate
;
Ultrasonography
10.Contrast-Enhanced Endoscopic Ultrasound for Differentially Diagnosing Autoimmune Pancreatitis and Pancreatic Cancer.
Min Keun CHO ; Sung Hoon MOON ; Tae Jun SONG ; Raymond E KIM ; Dong Wook OH ; Do Hyun PARK ; Sang Soo LEE ; Dong Wan SEO ; Sung Koo LEE ; Myung Hwan KIM
Gut and Liver 2018;12(5):591-596
BACKGROUND/AIMS: Differentially diagnosing focal-type autoimmune pancreatitis (f-AIP) and pancreatic cancer (PC) is challenging. Contrast-enhanced harmonic endoscopic ultrasound (CEH-EUS) may provide information for differentiating pancreatic masses. In this study, we evaluated the usefulness of CEH-EUS in differentiating f-AIP from PC. METHODS: Data were collected prospectively and analyzed on patients who underwent CEH-EUS between May 2014 and May 2015. Eighty consecutive patients were diagnosed with f-AIP or PC. PC and f-AIP were compared for enhancement intensity, contrast agent distribution, and internal vasculature. RESULTS: The study group comprised 53 PC patients and 27 f-AIP patients (17 with type-1 AIP [15 definite and two probable], two with probable type-2 AIP, and eight with AIP, not otherwise specified). Hyper- to iso-enhancement in the arterial phase (f-AIP, 89% vs PC, 13%; p < 0.05), homogeneous contrast agent distribution (f-AIP, 81% vs PC, 17%; p < 0.05), and absent irregular internal vessels (f-AIP, 85% vs PC, 30%; p < 0.05) were observed more frequently in the f-AIP group. The combination of CEH-EUS and enhancement intensity, absent irregular internal vessels improved the specificity (94%) in differentiating f-AIP from PC. CONCLUSIONS: CEH-EUS may be a useful noninvasive modality for differentially diagnosing f-AIP and PC. Combined CEH-EUS findings could improve the specificity of CEH-EUS in differentiating f-AIP from PC.
Biopsy, Fine-Needle
;
Contrast Media
;
Endosonography
;
Humans
;
Pancreatic Neoplasms*
;
Pancreatitis*
;
Prospective Studies
;
Sensitivity and Specificity
;
Ultrasonography*

Result Analysis
Print
Save
E-mail